study	group	count	intervention	measurement_type	substance	tissue	method	label	time	time_unit	mean	median	min	max	mean_sd	mean_se	cv	comments	mean_unit	median_unit
Alalawneh2024	obese	18.0	RIV20	cumulative amount	rivaroxaban	urine	LC/MS	rivaroxaban_urine_obese	3.32	hr	3.028356428374782e-06				1.995962191428834e-06			end collection interval	mole	mg
Alalawneh2024	obese	18.0	RIV20	cumulative amount	rivaroxaban	urine	LC/MS	rivaroxaban_urine_obese	6.11	hr	6.4696705515279434e-06				4.584057760488231e-06			end collection interval	mole	mg
Alalawneh2024	obese	18.0	RIV20	cumulative amount	rivaroxaban	urine	LC/MS	rivaroxaban_urine_obese	9.22	hr	9.589795356520144e-06				5.545156837296848e-06			end collection interval	mole	mg
Alalawneh2024	obese	18.0	RIV20	cumulative amount	rivaroxaban	urine	LC/MS	rivaroxaban_urine_obese	12.21	hr	1.1585757547948977e-05				5.893439523727494e-06			end collection interval	mole	mg
Alalawneh2024	obese	18.0	RIV20	cumulative amount	rivaroxaban	urine	LC/MS	rivaroxaban_urine_obese	15.24	hr	1.2709920161512344e-05				5.9996975758422046e-06			end collection interval	mole	mg
Alalawneh2024	obese	18.0	RIV20	cumulative amount	rivaroxaban	urine	LC/MS	rivaroxaban_urine_obese	18.28	hr	1.3283472515371204e-05				6.027050132874621e-06			end collection interval	mole	mg
